Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus docetaxel versus placebo plus docetaxel in previously platinum-treated advanced urothelial carcinoma
NL-OMON47462Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) and bladder cancer comparing Ramucirumab plus docetaxel with Placebo plus docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Aug 2015; status: completed.
02
Drugs
ramucirumabdocetaxel
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON47462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47462.